Author:
Okushin Kazuya,Tateishi Ryosuke,Hirakawa Shinya,Tachimori Hisateru,Uchino Koji,Nakagomi Ryo,Yamada Tomoharu,Nakatsuka Takuma,Minami Tatsuya,Sato Masaya,Fujishiro Mitsuhiro,Hasegawa Kiyoshi,Eguchi Yuichiro,Kanto Tatsuya,Yoshiji Hitoshi,Izumi Namiki,Kudo Masatoshi,Koike Kazuhiko
Abstract
AbstractThe number of cancer cases diagnosed during the coronavirus disease 2019 (COVID-19) pandemic has decreased. This study investigated the impact of the pandemic on the clinical practice of hepatocellular carcinoma (HCC) using a novel nationwide REgistry for Advanced Liver diseases (REAL) in Japan. We retrieved data of patients initially diagnosed with HCC between January 2018 and December 2021. We adopted tumor size as the primary outcome measure and compared it between the pre-COVID-19 (2018 and 2019) and COVID-19 eras (2020 and 2021). We analyzed 13,777 patients initially diagnosed with HCC (8074 in the pre-COVID-19 era and 5703 in the COVID-19 era). The size of the maximal intrahepatic tumor did not change between the two periods (mean [SD] = 4.3 [3.6] cm and 4.4 [3.6] cm), whereas the proportion of patients with a single tumor increased slightly from 72.0 to 74.3%. HCC was diagnosed at a similar Barcelona Clinic Liver Cancer stage. However, the proportion of patients treated with systemic therapy has increased from 5.4 to 8.9%. The proportion of patients with a non-viral etiology significantly increased from 55.3 to 60.4%. Although the tumor size was significantly different among the etiologies, the subgroup analysis showed that the tumor size did not change after stratification by etiology. In conclusion, the characteristics of initially diagnosed HCC remained unchanged during the COVID-19 pandemic in Japan, regardless of differences in etiology. A robust surveillance system should be established particularly for non-B, non-C etiology to detect HCC in earlier stages.
Funder
Ministry of Health, Labour and Welfare
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021).
2. Rumgay, H. et al. Global, regional and national burden of primary liver cancer by subtype. Eur. J. Cancer 161, 108–118 (2022).
3. Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 3, 1683–1691 (2017).
4. Kudo, M. et al. Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012–2013). Hepatol. Res. Off. J. Japan Soc. Hepatol. 52, 5–66 (2022).
5. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020–2021. Lancet 399, 1513–1536 (2022).